Skip to content

Public FDA record

Z-0831-2019: COBRA FUSION 150 Ablation System, Catalog # (REF) 700-001S

Recall record Z-0831-2019 for AtriCure, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0831-2019
Company in FDA record
AtriCure, Inc.
FDA record creation date
Feb 14, 2019
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

There is a potential for patients undergoing ablation to experience an elevated risk for TE; during stand-alone off-pump procedures where cardio pulmonary bypass (CPB) was not utilized.

Source facts

Action
On January 22, 2019, AtriCure distributed URGENT Advisory Notices to customers via certified mail. AtriCure is providing modifications to the existing Cobra Fusion Instruction for Use (IFU), to address contributing TE Factors associated with stand-alone off-pump procedures. These are in addition to the warnings and precautions that are present within the current IFU. Modifications to Warnings: When utilizing the Cobra Fusion device in a stand-alone off-pump (without CPB) procedure, the following should be considered: - Physicians should consider a comprehensive anti-coagulation protocol including pre-operative, intra-operative and post-operative anti-coagulation management to prevent potential thromboemboli. Modifications to Precautions: - Post-operative anti-coagulation therapy for protection against thromboemboli is inclusive of the bridging period between the end of the procedure and until effective therapeutic levels of Oral Anticoagulation (OAC) are achieved. Customers Should Take the following Action: - Read and follow the revised Instructions for Use IFU enclosed with the notification letter when using the Cobra Fusion. - Report any post ablation thromboembolic event with the Cobra Fusion, to AtriCure by phone at 1-866-349-2342 (select option 6) or e-mail to pcomplaints@atricure.com. - Return the completed Acknowledgement Form. Contact Information: If you have any questions, please contact Rob Cantu, Vice President of Quality at (1-513-644-4245) from 9-6pm ET on Mondays - Fridays. You may also contact customer service at (1-866-349-2342) any time of day, your message will be forwarded to Quality Assurance for review promptly. **Press Release will be issue depended on CDRH comment/review**
Initiated
2019-01-22
Root cause
Unknown/Undetermined by firm
Terminated
2020-05-12
Distribution
AL, AR, AZ, CA, CT, CO, FL, ID, IL, IN, KS, KY, LA, MD, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NV, NY, OH, OK, OR, PA, SC, TN, TX, UT, VA, WA & WI Internationally - Germany, Italy, Netherlands, France, Austria, United Kingdom, Poland, Czech Republic, United Arab Emirates, Sweden, Switzerland, Kuwait, Belgium and Latvia
Recall number
Z-0831-2019
Recall status
Terminated
CDRH record ID
170343
FDA record created
2019-02-14
Recall event number
81932

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗